Stifel Financial’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Stifel Financial’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2	Closed	-$19K	–	2837
2018 Q1	$19K	Hold	2	–	–	﹤0.01%	2674
2017 Q4	$27K	Hold	2	–	–	﹤0.01%	2611
2017 Q3	$64K	Hold	2	–	–	﹤0.01%	2506
2017 Q2	$124K	Sell	2 -1	-33%	-$54.6K	﹤0.01%	2437
2017 Q1	$194K	Buy	3 +1	+50%	+$80.8K	﹤0.01%	2339
2016 Q4	$176K	Hold	2	–	–	﹤0.01%	2287
2016 Q3	$283K	Hold	2	–	–	﹤0.01%	2012
2016 Q2	$241K	Buy	+2	New	+$235K	﹤0.01%	2169
2016 Q1	–	Sell	-2	Closed	-$268K	–	2448
2015 Q4	$268K	Hold	2	–	–	﹤0.01%	1974
2015 Q3	$312K	Buy	2 +1	+100%	+$234K	﹤0.01%	1806
2015 Q2	$178K	Buy	+1	New	+$264K	﹤0.01%	2195

Other funds holding NVIV

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

ICM

IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial's NVIV Position: Q2 2018 in Review

Stifel Financial sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2018, closing a stake of 2 shares — an estimated $19K sold.

Stifel Financial first reported a position in NVIV in Q2 2015 and held it in 11 quarters. The position peaked at $312K in Q3 2015. 17 funds tracked by Wall St. Rank hold NVIV as of Q2 2018.

Stifel Financial reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2018 after selling out during the quarter.
Stifel Financial sold 2 InVivo Therapeutics Holdings Corp shares in Q2 2018, an estimated $19K.
Stifel Financial first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 11 quarters.
Stifel Financial's InVivo Therapeutics Holdings Corp position peaked at $312K in Q3 2015.
17 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2018.

Based on Stifel Financial's 13F filing for Q2 2018, filed 14 Aug 2018.